232 related articles for article (PubMed ID: 21825240)
1. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A
Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
3. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Zappia M; Annesi G; Nicoletti G; Arabia G; Annesi F; Messina D; Pugliese P; Spadafora P; Tarantino P; Carrideo S; Civitelli D; De Marco EV; Cirò-Candiano IC; Gambardella A; Quattrone A
Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
Suh DC; Pahwa R; Mallya U
J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
Hashim HZ; Norlinah MI; Nafisah WY; Tan HJ; Raymond AA; Tamil AM
Int J Neurosci; 2014 Mar; 124(3):187-91. PubMed ID: 23952588
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Stathis P; Konitsiotis S; Tagaris G; Peterson D;
Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
[TBL] [Abstract][Full Text] [Related]
10. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
[TBL] [Abstract][Full Text] [Related]
11. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
12. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
13. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
[TBL] [Abstract][Full Text] [Related]
14. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
15. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
16. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
[TBL] [Abstract][Full Text] [Related]
17. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
18. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
20. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
Mann RK; Edwards R; Zhou J; Jog M; Duval C
Clin Neurol Neurosurg; 2010 Jun; 112(5):392-9. PubMed ID: 20206438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
